Laurel Lee From Florida's 15th District Makes Notable Trades in Apple, GE Vernova, and Pfizer
Pfizer Meets Amyloidosis Rival as BridgeBio Wins FDA Nod for Attruby
These 4 Measures Indicate That Pfizer (NYSE:PFE) Is Using Debt Extensively
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
BridgeBio Gets US Approval for Heart Drug to Compete With Pfizer
Pfizer Options Spot-On: On November 22nd, 411.31K Contracts Were Traded, With 3.36 Million Open Interest
On November 22nd ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 411.31K options for the day, of which put options accounted for 24.82% of the total transactions, and
Pfizer Inc. (PFE) Jefferies London Healthcare Conference (Transcript)
Pfizer Stock Drops 10% In November On News Of Kennedy's HHS Nomination
Pfizer Options Spot-On: On November 21st, 265.78K Contracts Were Traded, With 3.35 Million Open Interest
On November 21st ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 265.78K options for the day, of which put options accounted for 47.97% of the total transactions, and
Optimism Over Global Healthcare Sector Rises: Jefferies
Watching Shares Of Vaccine Stocks; Traders Circulate Article Titled "Top FDA Vaccine Official Says RFK Jr. Nomination Is a Chance for Scientist to Make the Case for Vaccines"
Live On CNBC, Josh Brown Announces Cut Pfizer Position By Half
Pyxis Stock Craters 46% Amid Phase 1 Data, William Blair Downgrade
Pfizer Names New Head Of Research And Development
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 5% Dividend Yields
Sector Update: Health Care Stocks Rise Pre-Bell Thursday
The Zacks Analyst Blog Highlights Adobe, Pfizer, Dollar General, Snap and Ryanair
pfizer's (PFE.US) long-acting hemophilia therapy has been approved in the European Union.
On November 20, pfizer (PFE.US) announced that the European Commission (EC) has approved Hympavzi (marstacimab) for market release.
Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
EC Marketing Authorisation Granted to Pfizer's HYMPAVZI for Haemophilia